SAN FRANCISCO, March 27 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that David Hung, M.D., president and chief executive officer, will participate in Leerink Swann & Company’s Roundtable Conference entitled “A Mind Is a Terrible Thing to Waste: Emerging Treatments for Alzheimer’s Disease,” on Tuesday, April 3, at Le Parker Meridien in New York. Dr. Hung will present at 9:15 a.m. Eastern Time.
Dr. Hung will provide an overview of Medivation and its clinical development program for Dimebon(TM) for Alzheimer’s disease.
Full top-line data from Medivation’s Phase 2 efficacy study of Dimebon in Alzheimer’s disease were presented at the 8th International Conference on Alzheimer’s and Parkinson’s Diseases: Progress and New Perspectives in Salzburg, Austria, on March 18. Six-month results from this randomized, double-blinded, placebo-controlled trial of Dimebon in patients with mild-to- moderate Alzheimer’s disease demonstrated that patients treated with Dimebon were significantly improved compared to patients taking placebo on all five efficacy endpoints studied, which assessed cognitive function, memory, ability to perform tasks of daily living, global function and behavior. Dimebon was well tolerated in this study.
A live audio webcast of Dr. Hung’s presentation will be available on the “Events and Presentations” page of the “Investor Relations” section of the Company’s website at http://www.medivation.com. A replay will also be available for 30 days following the live presentation.
About Medivation
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation’s current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer’s disease, Huntington’s disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company’s product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company’s financial and operating results.
Medivation, Inc.
CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,+1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners,+1-415-946-1064
Web site: http://www.medivation.com//
